Mga Batayang Estadistika
| CIK | 1828253 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Evaxion A/S - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive |
|
| August 27, 2025 |
Evaxion to present at several conferences during the second half of 2025 EXHIBIT 99.1 Evaxion to present at several conferences during the second half of 2025 Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be p |
|
| August 14, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report and the section contained in our Annual Report on Fo |
|
| August 14, 2025 |
Evaxion announces business update and second quarter 2025 financial results EXHIBIT 99.1 Evaxion announces business update and second quarter 2025 financial results COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces second quarter 2025 financial results. Business highlights (since last quarterly update) Evaxion con |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| August 14, 2025 |
EVAXION BIOTECH A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Exhibit 99.1 EVAXION BIOTECH A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 2 Unaudited Condensed Consolidated Interim Statements of Financial Position as of June 30, 2025 and December 31, 2024 3 Unaudited Condensed Consolidated Interi |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive |
|
| August 11, 2025 |
Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 EXHIBIT 99.1 Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, befor |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive of |
|
| July 25, 2025 |
EXHIBIT 99.1 Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 t |
|
| July 17, 2025 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of July , 2025, between Evaxion A/S, a public limited liability company incorporated under the laws of the Kingdom of Denmark (the “Company”), and European Investment Bank, having its seat at 100 blvd Konrad Adenauer, Luxembourg, L-2950 Luxembourg (the “Warrant Holder”). Thi |
|
| July 17, 2025 |
Exhibit 10.2 Appendix 11 WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES EVAXION BIOTECH A/S Warrant ADSs: Initial Exercise Date: January 31, 2025 THIS WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the l |
|
| July 17, 2025 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION A/S CVR-nr. 31762863 Exhibit 3.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion A/S. Selskabet driver tillige virksomhed under binavnene Evaxion Biotech A/S og NovVac A/S. 1.1 The name of the Company is Evaxion A/S. The Company also carries on business under the secondary names Evaxion Biotech A/S and NovVac A/S. 1.2 Selsk |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive |
|
| July 17, 2025 |
STRICTLY CONFIDENTIAL - LEGAL PRIVILEGE Exhibit 10.3 EXECUTION VERSION ADVOKATPARTNERSELSKAB STRICTLY CONFIDENTIAL - LEGAL PRIVILEGE AMENDMENT AGREEMENT FINANCE CONTRACT DATED 6 AUGUST 2020; SERAPIS NO. 2019-0227; FI NO. 90935 Between The European Investment Bank as Bank and Evaxion A/S as Borrower TABLE OF CONTENTS 1 DEFINITIONS AND INTERPRETATION 3 2 AMENDMENTS TO THE EXISTING FINANCE CONTRACT 4 3 PARTIAL PREPAYMENT OF TRANCHE A 5 4 R |
|
| July 17, 2025 |
Exhibit 10.1 Debt Settlement Agreement relating to originally EUR 20,000,000 Finance Contract originally dated 6 August 2020 and Warrant Agreement originally dated 27 November 2020 11 July 2025 between EVAXION A/S as Borrower and EUROPEAN INVESTMENT BANK as Bank Table of Contents 1 Definitions and Interpretation 3 2 Partial Debt Cancellation of Tranche A and Issuance of New Warrants 4 3 Cost and E |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive of |
|
| July 11, 2025 |
Evaxion finalizes agreement with EIB to convert debt into equity EXHIBIT 99.1 Evaxion finalizes agreement with EIB to convert debt into equity Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion’s €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth of ordinary Evaxion warrants EIB will purchase the warrants at a price of $4.87 corresponding to a premium of 89% to the sh |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive of |
|
| July 2, 2025 |
EXHIBIT 99.1 Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO has commenced Thomas Schmidt appointed permanent Chief Financial Officer COPENHAGEN, Denmark, July 1, 2025 - Evaxion A |
|
| June 25, 2025 |
Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus Initial computational analysis demonstrated that Evaxion’s AI-Immunology™ platform can identify novel vaccine targets to combat Group A Streptococcus (GAS) New vaccine program is added to Evaxion’s pipeline under the name EVX-B4 Urgent need for preventive measures a |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive of |
|
| June 3, 2025 |
Evaxion receives grant funding to design new polio vaccine EXHIBIT 99.1 Evaxion receives grant funding to design new polio vaccine Evaxion awarded a grant from the Gates Foundation Grant funds research aimed at ultimately eradicating polio, a highly infectious viral disease Evaxion will apply its leading AI-Immunology™ platform to identify and combine various antigens to combat the virus and develop design options for a potential new vaccine construct Ris |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive of |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive off |
|
| May 27, 2025 |
Evaxion announces business update and first quarter 2025 financial results EXHIBIT 99.1 Evaxion announces business update and first quarter 2025 financial results COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial results. Business highlights (since last quarterly update) Evaxion has made |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive off |
|
| May 23, 2025 |
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 EXHIBIT 99.1 Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on Tuesday, May 27, 2025, before opening o |
|
| May 22, 2025 |
EXHIBIT 99.1 Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package Will provide insights into the durability of immune and clinical responses |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive off |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal ex |
|
| May 5, 2025 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION A/S CVR-nr. 31762863 Exhibit 3.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion A/S. Selskabet driver tillige virksomhed under binavnene Evaxion Biotech A/S og NovVac A/S. 1.1 The name of the Company is Evaxion A/S. The Company also carries on business under the secondary names Evaxion Biotech A/S and NovVac A/S. 1.2 Selsk |
|
| April 29, 2025 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skabe |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| April 28, 2025 |
EXHIBIT 99.1 80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting 80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidates The data underscores the precision of Evaxion’s AI-Immunology™ platform i |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal exe |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal exe |
|
| April 10, 2025 |
Evaxion to present at World Vaccine Congress EXHIBIT 99.1 Evaxion to present at World Vaccine Congress Congress will take place April 21-24, 2025, in Washington, D.C. COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two presentations and man a booth at the World Vaccine Congress taking place April 21-24, |
|
| April 7, 2025 |
Exhibit 99.1 4 April 2025 NOTICE OF ANNUAL GENERAL MEETING EVAXION BIOTECH A/S 30 APRIL 2025 AT 14:00 (CEST) The board of directors hereby convenes the annual general meeting of Evaxion Biotech A/S, company registration (CVR) no. 31 76 28 63 (the "Company"), to be held on 30 APRIL 2025 AT 14:00 (CEST) at Evaxion Biotech A/S, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark. AGENDA 1. Election of the c |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal execu |
|
| April 7, 2025 |
Exhibit 99.2 The Annual General Meeting of Evaxion Biotech A/S will be held on 30 April 2025 at 2:00 pm (CEST) at Evaxion Biotech A/S, Dr. Neergaards Vej 5F, 2970 Hørsholm, Denmark Name and address: This form must be returned to: Computershare A/S Lottenborgvej 26D DK-2800 Kgs. Lyngby VP account number: Denmark Request admission card Admission cards may be requested and proxies nominated electroni |
|
| April 1, 2025 |
Exhibit 11.1 INTERNAL RULES ON INSIDER TRADING POLICY INTERNAL RULES ON INSIDER TRADING POLICY (Company registration no. (CVR) 31762863) PREAMBLE Evaxion Biotech A/S (the "Company” and, together with its subsidiaries, the "Group") has American Depositary Shares ("ADSs") representing ordinary shares of the Company listed on The NASDAQ Capital Market, New York. These internal rules apply to these AD |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 1, 2025 |
Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002* In connection with the Annual Report on Form 20-F of Evaxion Biotech A/S (the “Company”) for the year ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersig |
|
| April 1, 2025 |
Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christian Kanstrup, certify that: 1. I have reviewed this annual report on Form 20-F of Evaxion Biotech A/S (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| April 1, 2025 |
Evaxion announces business update and full year 2024 financial results EXHIBIT 99.1 Evaxion announces business update and full year 2024 financial results COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financial results. Business highlights 2024 and the first months of 2025 saw Evaxion |
|
| April 1, 2025 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002* In connection with the Annual Report on Form 20-F of Evaxion Biotech A/S (the “Company”) for the year ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, |
|
| April 1, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S-8 No. 333-255064) Pertaining to the Incentive Scheme of Evaxion Biotech A/S, (2) Registration Statement (Form F-3 No. 333-265132) of Evaxion Biotech A/S; (3) Registration Statement (Form F-1 No. 333-266050) o |
|
| April 1, 2025 |
EVAXION BIOTECH A/S INCENTIVE COMPENSATION RECOUPMENT POLICY Exhibit 97.1 EVAXION BIOTECH A/S INCENTIVE COMPENSATION RECOUPMENT POLICY 1. Introduction. The Board of Directors (the “Board”) of Evaxion Biotech A/S (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal exe |
|
| April 1, 2025 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Thomas Frederik Schmidt, certify that: 1. I have reviewed this annual report on Form 20-F of Evaxion Biotech A/S (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make t |
|
| March 27, 2025 |
Evaxion to announce business update and full year 2024 financial results on April 1, 2025 EXHIBIT 99.1 Evaxion to announce business update and full year 2024 financial results on April 1, 2025 COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before openin |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal exe |
|
| March 26, 2025 |
Evaxion Biotech A/S Up to $4,480,000 American Depositary Shares representing Ordinary Shares TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-285778 PROSPECTUS SUPPLEMENT (to Prospectus dated March 24, 2025) Evaxion Biotech A/S Up to $4,480,000 American Depositary Shares representing Ordinary Shares We have previously entered into a Capital on Demand™ Sales Agreement, or the Sales Agreement, with JonesTrading Institutional Services LLC, or Jones, relating to the s |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal exe |
|
| March 25, 2025 |
EXHIBIT 99.1 Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the already strong clinical data package for EVX-01 The trial remains on track for tw |
|
| March 20, 2025 |
Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Hørsholm Telephone: +45 31 31 97 53 Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Hørsholm Denmark Telephone: +45 31 31 97 53 March 20, 2025 U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. Tyler Howes Re: Evaxion Biotech A/S Registration Statement on Form F-3 (File No. 333- 285778) Acceleration Request Requested Date: |
|
| March 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Evaxion Biotech A/S (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title (1) Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price (2) Fee Rate Amount of Regi |
|
| March 13, 2025 |
As filed with the Securities and Exchange Commission on March 13, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 13, 2025 Registration Statement No. |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal exe |
|
| March 4, 2025 |
Evaxion to present at numerous upcoming conferences EXHIBIT 99.1 Evaxion to present at numerous upcoming conferences Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming weeks and months COPENHAGEN, Denmark, March 4, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting at several |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| February 25, 2025 |
EXHIBIT 99.1 Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further insights into potential enhanced treatment effects and durability of induced im |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| February 14, 2025 |
Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination EXHIBIT 99.1 Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders’ equity requirement Evaxion has restored its equity above the minimum requirement through capital market activities Evaxion’s cash runway now extends to mid-2026 The conversion of Evaxion’s EIB |
|
| February 12, 2025 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skabe |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of princip |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| January 31, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-283304 UP TO 3,997,361 AMERICAN DEPOSITARY SHARES REPRESENTING 199,868,050 ORDINARY SHARES AND UP TO 1,998,675 WARRANTS TO PURCHASE UP TO 1,998,675 AMERICAN DEPOSITARY SHARES (and 1,998,675 American Depositary Shares representing 99,933,750 ordinary shares issuable upon exercise of the Warrants) Evaxion Biotech A/S We are |
|
| January 31, 2025 |
Evaxion announces closing of $10.8 million public offering EXHIBIT 99.1 Evaxion announces closing of $10.8 million public offering COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares (“ADSs”) and warrants to purchase u |
|
| January 30, 2025 |
Evaxion announces pricing of $10.8 million public offering EXHIBIT 99.1 Evaxion announces pricing of $10.8 million public offering COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares (“ADSs”) and warrants to purchase u |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| January 28, 2025 |
Exhibit 10.18 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of [·], 2025, is between Evaxion Biotech A/S, a public limited liability company incorporated under the laws of the Kingdom of Denmark (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the |
|
| January 28, 2025 |
As filed with the Securities and Exchange Commission on January 28, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 28, 2025 Registration Statement No. |
|
| January 28, 2025 |
Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Hørsholm Telephone: +45 31 31 97 53 January 28, 2025 Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Hørsholm Denmark Telephone: +45 31 31 97 53 January 28, 2025 U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. Tyler Howes Re: Evaxion Biotech A/S Registration Statement on Form F-1 (File No. 333-283304) Acceleration Request Requested Date |
|
| January 28, 2025 |
EXHIBIT 99.1 Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirement Evaxion has currently restored its equity above the minimum requirement through exercise of prefunded warrants and sales |
|
| January 28, 2025 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [·], 2025 Christian Kanstrup Chief Executive Officer Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Horsholm Denmark Dear Mr. Kanstrup: This letter agreement (the “Agreement”) constitutes the agreement between Lake Street Capital Markets, LLC (“Lake Street”) and JonesTrading Institutional Services LLC (“Jones”), as placement agents (collectively, the “Placeme |
|
| January 27, 2025 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skabe |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principa |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principa |
|
| January 21, 2025 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skabe |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| January 15, 2025 |
Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now |
|
| January 14, 2025 |
Evaxion announces completion of ADS ratio change EXHIBIT 99.1 Evaxion announces completion of ADS ratio change COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company’s previously disclosed ratio change of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| January 10, 2025 |
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change EXHIBIT 99.1 Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it is amending the effective date for its plans to change the ratio of its American Depositary Sha |
|
| January 7, 2025 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skabe |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principa |
|
| December 30, 2024 |
Evaxion announces plan to implement ADS ratio change EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Evaxion announces plan to implement ADS ratio change COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| December 26, 2024 |
17 January 2025 AT 15:00 (CET) Exhibit 99.1 20 December 2024 NOTICE OF EXTRAORDINARY GENERAL MEETING EVAXION BIOTECH A/S 17 JANUARY 2025 AT 15:00 (CET) The board of directors hereby convenes an extraordinary general meeting of Evaxion Biotech A/S, company registration (CVR) no. 31 76 28 63 (the "Company"), to be held on 17 January 2025 AT 15:00 (CET) at Evaxion Biotech A/S, Dr Neergaards Vej 5F, DK-2970 Hørsholm, Denmark. AGEND |
|
| December 26, 2024 |
Exhibit 99.2 The Extraordinary General Meeting of Evaxion Biotech A/S will be held on Friday 17 January 2025 at 3:00 pm (CET) at Evaxion Biotech A/S, Dr. Neergaards Vej 5F, 2970 Hørsholm, Denmark Name and address: This form must be returned to: Computershare A/S Lottenborgvej 26D VP account number: DK-2800 Kgs. Lyngby Denmark Request admission card Admission cards may be requested and proxies nomi |
|
| December 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of princip |
|
| December 17, 2024 |
Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity EXHIBIT 99.1 Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity Evaxion and the European Investment Bank (EIB) are in advanced discussions about conversion of €3.5 million out of Evaxion’s €7 million loan with EIB into an equity-type instrument Such conversion is expected to increase Evaxion’s equity by $3.7 million immediately upon completion The conversio |
|
| December 17, 2024 |
As filed with the Securities and Exchange Commission on December 17, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 17, 2024 Registration Statement No. |
|
| December 17, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [•], 2024 Christian Kanstrup Chief Executive Officer Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Horsholm Denmark Dear Mr. Kanstrup: This letter agreement (the “Agreement”) constitutes the agreement between Lake Street Capital Markets, LLC (“Lake Street”), as placement agent (the “Placement Agent”) and Evaxion Biotech A/S, a public limited liability compan |
|
| December 17, 2024 |
Exhibit 10.18 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of [·], 2024, is between Evaxion Biotech A/S, a public limited liability company incorporated under the laws of the Kingdom of Denmark (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the |
|
| December 17, 2024 |
PREFUNDED WARRANT TO SUBSCRIBE FOR ORDINARY SHARES Exhibit 4.7 PREFUNDED WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES EVAXION BIOTECH A/S Warrant ADSs: Initial Exercise Date: , 2024 THIS PREFUNDED WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject t |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| December 17, 2024 |
Exhibit 4.8 WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES EVAXION BIOTECH A/S Warrant ADSs: Initial Exercise Date: , 2024 THIS WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise |
|
| December 17, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM F-1 (Form Type) Evaxion Biotech A/S (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares DKK 1 nominal value (1)(2)(3) 457(o) — — $ 10,850,000 0. |
|
| December 12, 2024 |
Evaxion establishes new AI-derived precision cancer vaccine concept EXHIBIT 99.1 Evaxion establishes new AI-derived precision cancer vaccine concept Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patients Novel preclinical data confirms the effectiveness of the precision vaccine approach by inducing strong T-cell responses and tumor growth inhibition in mice, thereby |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| December 9, 2024 |
Evaxion announces 2025 milestones reflecting continued strong strategy execution EXHIBIT 99.1 Evaxion announces 2025 milestones reflecting continued strong strategy execution With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025 The 2025 key milestones reflect all parts of Evaxion’s strategy for value realization Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025 COPENH |
|
| December 5, 2024 |
Exhibit 10.18 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of [·], 2024, is between Evaxion Biotech A/S, a public limited liability company incorporated under the laws of the Kingdom of Denmark (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the |
|
| December 5, 2024 |
As filed with the Securities and Exchange Commission on December 5, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 5, 2024 Registration Statement No. |
|
| December 5, 2024 |
PREFUNDED WARRANT TO SUBSCRIBE FOR ORDINARY SHARES Exhibit 4.7 PREFUNDED WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES EVAXION BIOTECH A/S Warrant ADSs: Initial Exercise Date: , 2024 THIS PREFUNDED WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject t |
|
| December 5, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [•], 2024 Christian Kanstrup Chief Executive Officer Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Horsholm Denmark Dear Mr. Kanstrup: This letter agreement (the “Agreement”) constitutes the agreement between Lake Street Capital Markets, LLC (“Lake Street”), as placement agent (the “Placement Agent”) and Evaxion Biotech A/S, a public limited liability compan |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| December 3, 2024 |
EXHIBIT 99.1 Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress COPENHAGEN, Denmark, December 2, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present preclinical Proof-of-Concept for its precision cancer vaccine concept, |
|
| November 18, 2024 |
As filed with the Securities and Exchange Commission on November 18, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 18, 2024 Registration Statement No. |
|
| November 18, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM F-1 (Form Type) Evaxion Biotech A/S (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares DKK 1 nominal value (1)(2)(3) 457(o) — — $ 12,500,000. |
|
| November 14, 2024 |
SC 13G 1 armistice-evax093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Evaxion Biotech A/S (Name of Issuer) American Depositary Shares, each representing ten ordinary shares, nominal value DKK 1 per share (Title of Class of Securities) 29970R204 (CUSIP Number) September 30, 2024 (Date of Event |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| November 13, 2024 |
EXHIBIT 99.1 Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing As anticipated, Evaxion has received a delisting determination The determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with Nasdaq’s equity requirement Evaxion remain committed to ensuring compliance and maintai |
|
| November 13, 2024 |
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1 EXHIBIT 99.1 Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1 New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also showcase the successful design of a proprietary prefusion glycoprotein B (gB) antigen with ability to neutralize the virus Evaxion is advancing t |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of princip |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| November 13, 2024 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at ska |
|
| November 6, 2024 |
SC 13G/A 1 ff408710013ga1-evaxion.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Evaxion Biotech A/S (Name of Issuer) Ordinary Shares, DKK 1 nominal value per share (Title of Class of Securities) 29970R204** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| October 31, 2024 |
Evaxion announces business update and third quarter 2024 financial results EXHIBIT 99.1 Evaxion announces business update and third quarter 2024 financial results COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results. Business highlights (since last quarterly update) Sinc |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| October 28, 2024 |
Evaxion to announce business update and third quarter 2024 financial results on October 31 EXHIBIT 99.1 Evaxion to announce business update and third quarter 2024 financial results on October 31 COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, be |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| October 9, 2024 |
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials EXHIBIT 99.1 Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked AI-Immunology™ vaccine targets, thereby linking AI-vaccine design with real-world evidence This underscore |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| October 4, 2024 |
EdgarFiling EXHIBIT 99.1 Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through iterative learning and the integration of advanced bioinformatics an |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principa |
|
| October 3, 2024 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at ska |
|
| October 1, 2024 |
OPTION AND LICENSE AGREEMENT by and between EVAXION BIOTECH A/S MERCK SHARP & DOHME LLC Exhibit 10.1 [****] This symbol identifies certain confidential information contained in this document that has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL EXECUTION VERSION OPTION AND LICENSE AGREEMENT by and between EVAXION BIOTECH A/S and MERCK SHARP & DOHME LLC [****] This symbol identifies certain confidential in |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principa |
|
| September 26, 2024 |
Evaxion significantly expands vaccine development collaboration with MSD EXHIBIT 99.1 Evaxion significantly expands vaccine development collaboration with MSD Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3 Evaxion will host a conference call and webcast to discuss the agreement on September 27, 2024 COPENHAGEN, Denmark, Sept. 26, 2024 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of princi |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| September 19, 2024 |
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction EXHIBIT 99.1 Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction feature The launch will expectedly improve Evaxion’s ability to fast and effectively discover AI-derived novel vaccines and is expected to furth |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| September 16, 2024 |
EXHIBIT 99.1 Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16 patients had a reduction of their tumors (target lesions) 79% of EVX-01’s vaccine targets triggered a targeted immune response, which compares very favorably to what i |
|
| September 9, 2024 |
EXHIBIT 99.1 Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01 Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16 patients had reduction of their tumors (target lesions) The complete one-year dataset wil |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| September 9, 2024 |
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2 EXHIBIT 99.1 Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2 New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteria The data confirm that Evaxion’s AI-Immunology™ platform is delivery modality agnostic COPENHAGEN, Den |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| August 23, 2024 |
19,453,796 ORDINARY SHARES REPRESENTED BY 1,945,379 AMERICAN DEPOSITARY SHARES Evaxion Biotech A/S TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-279153 19,453,796 ORDINARY SHARES REPRESENTED BY 1,945,379 AMERICAN DEPOSITARY SHARES Evaxion Biotech A/S This prospectus relates to the offer and sale by the selling shareholders identified in this prospectus of up to an aggregate of 19,453,796 ordinary shares, DKK 1 nominal value per share, represented by 1,945,379 America |
|
| August 20, 2024 |
Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Hørsholm Telephone: +45 31 31 97 53 Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Hørsholm Denmark Telephone: +45 31 31 97 53 August 20, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington D.C. 20549-4720 Attn: Jessica Dickerson Jason Drory Re: Evaxion Biotech A/S Registration Statement on Form F-1 (File No. 333-279153) Acceleration Request Requested Date: |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 20, 2024 Registration Statement No. |
|
| August 19, 2024 |
VEDTÆGTER / ARTICLES OF AS- EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF AS- SOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skab |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| August 14, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report and the section contained in our Annual Report on Fo |
|
| August 14, 2024 |
FORM 6-K EVAXION BIOTECH A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Exhibit 99.1 FORM 6-K EVAXION BIOTECH A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 2 Unaudited Condensed Consolidated Interim Statements of Financial Position as of June 30, 2024 and December 31, 2023 3 Unaudited Condensed Consolidat |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| August 14, 2024 |
Evaxion Announces Business Update and Second Quarter 2024 Financial Results EXHIBIT 99.1 Evaxion Announces Business Update and Second Quarter 2024 Financial Results COPENHAGEN, Denmark, Aug. 14, 2024 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces second quarter 2024 financial results. Business Highlights Since Last Quarter |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal ex |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal ex |
|
| August 12, 2024 |
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14 EXHIBIT 99.1 Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14 COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal ex |
|
| August 8, 2024 |
EXHIBIT 99.1 Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is proud to announce the presentation |
|
| August 2, 2024 |
6-K 1 f6k080224.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm |
|
| July 22, 2024 |
NEW YORK LONDON SINGAPORE PHILADELPHIA CHICAGO WASHINGTON, DC SAN FRANCISCO SILICON VALLEY SAN DIEGO LOS ANGELES BOSTON HOUSTON DALLAS FORT WORTH AUSTIN FIRM and AFFILIATE OFFICES www. |
|
| July 22, 2024 |
As filed with the Securities and Exchange Commission on July 22, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 22, 2024 Registration Statement No. |
|
| July 16, 2024 |
EXHIBIT 99.1 Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and proprieta |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal exec |
|
| July 3, 2024 |
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update EXHIBIT 99.1 Evaxion Reinforces Milestone Timeline and Provides Shareholder Update COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders. Dear Fellow Shareholders of Evaxion, The first half of |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal exec |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal exec |
|
| July 2, 2024 |
PATENT CO-OWNERSHIP AGREEMENT PATENT CO-OWNERSHIP AGREEMENT Exhibit 10.1 [****] This symbol identifies certain confidential information contained in this document that has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. PATENT CO-OWNERSHIP AGREEMENT PATENT CO-OWNERSHIP AGREEMENT This agreement (“Agreement”) between EVAXION BIOTECH A/S, CVR No. DK 3176 2863, a company incorporated under the law |
|
| July 2, 2024 |
Exhibit 10.1 [****] This symbol identifies certain confidential information contained in this document that has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENSE AGREEMENT CAF®09b Patent, Know How & Trademark Licence Agreement DATED 27 June 2024 between (1) Statens Serum Institut - and - (2) Evaxion Biotech A/S [****] This symbo |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| June 26, 2024 |
EXHIBIT 99.1 Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive na |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal exec |
|
| June 24, 2024 |
Exhibit 10.1 27.5.2024 Ref. 61047/LLJ ID 6187 AMENDMENT TO WARRANTS TO SUBSCRIBE FOR ORDINARY SHARES, of DKK 1.00 nominal value per share, of evaxion biotech A/S AND ISSUED on 21 December 2023 ON THE TERMS AND CONDITIONS SET FORTH IN APPENDIX 6 TO THE ARTICLES OF ASSOCIATION OF eVAXION BIOTECH a/s THIS AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT DATED 18 DECEMBER, 2023 REGARDING INTER ALIA WARR |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| June 17, 2024 |
EXHIBIT 99.1 Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s personalized cancer vaccine, EVX-01, in patients with metastatic melanoma The findings also |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Translation of registrant's name into English) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive o |
|
| June 7, 2024 |
VEDTÆGTER / ARTICLES OF AS- EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF AS- SOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skab |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal e |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Translation of registrant's name into English) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive o |
|
| June 3, 2024 |
EXHIBIT 99.1 Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024 Evaxion’s AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patients Findings further confirm and validate the precision and predictive power of Evaxion’s AI vaccine target dis |
|
| June 3, 2024 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skabe |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Translation of registrant's name into English) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive of |
|
| May 28, 2024 |
Evaxion Announces Business Update and First Quarter 2024 Financial Results EXHIBIT 99.1 Evaxion Announces Business Update and First Quarter 2024 Financial Results COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2024 financial results. Business Highlights Sinc |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal ex |
|
| May 24, 2024 |
Exhibit 10.1 AMENDMENT TO SERIES A WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES THIS AMENDMENT TO SERIES A WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Amendment”), dated as of May , 2024, is entered into by and between Evaxion Biotech A/S, a public limited liability company incorporated under the laws of the Kingdo |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Translation of registrant's name into English) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive of |
|
| May 23, 2024 |
EXHIBIT 99.1 Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024 EVX-01 induced positive clinically relevant immune responses in all assessed patients Booster immunizations tended to increase the immune response The observed immune responses were mediated by both CD4+ and CD8+ T-cells COPE |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Translation of registrant's name into English) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive of |
|
| May 10, 2024 |
Evaxion Receives Nasdaq Notification EXHIBIT 99.1 Evaxion Receives Nasdaq Notification COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on May 7, 2024, it received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications |
|
| May 6, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM F-1 (Form Type) Evaxion Biotech A/S (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares DKK 1 nominal value (1) 457(c) 19,453,796 0. |
|
| May 6, 2024 |
As filed with the Securities and Exchange Commission on May 6, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 6, 2024 Registration Statement No. |
|
| April 25, 2024 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 3.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skabe |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| April 17, 2024 |
EXHIBIT 99.1 Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01 Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing Favorable safety profile confirmed Trial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) - Evaxion |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Translation of registrant's name into English) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Translation of registrant's name into English) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive |
|
| April 2, 2024 |
EXHIBIT 99.1 Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infections The vaccine antigens significantly protected large, non-rodent animals against surgical |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| March 29, 2024 |
Exhibit 99.2 The Annual General Meeting of Evaxion Biotech A/S will be held on 16 April 2024 at 3:00 pm (CEST) at Evaxion Biotech A/S, Dr. Neergaards Vej 5F, 2970 Hørsholm, Denmark Name and address: This form must be returned to: Computershare A/S Lottenborgvej 26D DK-2800 Kgs. Lyngby VP account number: Denmark Request admission card Admission cards may be requested and proxies nominated electroni |
|
| March 29, 2024 |
Exhibit 99.1 26 March 2024 NOTICE OF ANNUAL GENERAL MEETING EVAXION BIOTECH A/S 16 APRIL 2024 AT 15:00 (CEST) The board of directors hereby convenes the annual general meeting of Evaxion Biotech A/S, company registration (CVR) no. 31 76 28 63 (the “Company”), to be held on 16 APRIL 2024 AT 15:00 (CEST) at Evaxion Biotech A/S, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark. AGENDA 1. Election of the |
|
| March 27, 2024 |
Evaxion Announces Business Update and Full Year 2023 Financial Results EXHIBIT 99.1 Evaxion Announces Business Update and Full Year 2023 Financial Results Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous retroviruses (ERVs), broadening the potential of cancer vaccines. Successful completion of initial phases of |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Translation of registrant's name into English) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive |
|
| March 26, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S-8 No. 333-255064) Pertaining to the Incentive Scheme of Evaxion Biotech A/S, (2) Registration Statement (Form F-3 No. 333-265132) of Evaxion Biotech A/S, (3) Registration Statement (Form F-1 No. 333-266050) o |
|
| March 26, 2024 |
Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jesper Nyegaard Nissen, certify that: 1. I have reviewed this annual report on Form 20-F of Evaxion Biotech A/S (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make th |
|
| March 26, 2024 |
Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christian Kanstrup, certify that: 1. I have reviewed this annual report on Form 20-F of Evaxion Biotech A/S (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| March 26, 2024 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002* In connection with the Annual Report on Form 20-F of Evaxion Biotech A/S (the “Company”) for the year ended December 31, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, |
|
| March 26, 2024 |
Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002* In connection with the Annual Report on Form 20-F of Evaxion Biotech A/S (the “Company”) for the year ended December 31, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersig |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 19, 2024 |
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform EXHIBIT 99.1 Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologies AI-Immunology™ outcompetes standard vaccine target discovery approaches and holds the promise of addressing serious unmet needs Wi |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Translation of registrant's name into English) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive |
|
| March 13, 2024 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skabe |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Translation of registrant's name into English) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executi |
|
| February 29, 2024 |
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations EXHIBIT 99.1 Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces that it will host a Research & Development (R&D) Day focusing on its |
|
| February 20, 2024 |
EXHIBIT 99.1 Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccin |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of princip |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of princip |
|
| February 7, 2024 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skabe |
|
| February 7, 2024 |
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05, 2024, it received a Notification Letter from the Listing Qualificatio |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of princip |
|
| February 6, 2024 |
Evaxion Announces Closing of $15 Million Public Offering Exhibit 99.1 Evaxion Announces Closing of $15 Million Public Offering COPENHAGEN, Denmark, Feb. 6, 2024 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing on February 5, 2024 of its previously announced public offering of 3,750,000 of its America |
|
| February 5, 2024 |
Exhibit 99.2 EXHIBIT A-1 PREFUNDED WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES EVAXION BIOTECH A/S Warrant ADSs: Initial Exercise Date: , 2024 THIS PREFUNDED WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subjec |
|
| February 5, 2024 |
Exhibit 99.3 EXHIBIT A-2 SERIES A WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES EVAXION BIOTECH A/S Warrant ADSs: Initial Exercise Date: February , 2024 THIS SERIES A WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and |
|
| February 5, 2024 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of February 1, 2024, is between Evaxion Biotech A/S, a public limited liability company incorporated under the laws of the Kingdom of Denmark (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectivel |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of princip |
|
| February 5, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-276505 PROSPECTUS 757,500 AMERICAN DEPOSITARY SHARES REPRESENTING 7,575,000 ORDINARY SHARES AND 2,992,500 PRE-FUNDED WARRANTS TO PURCHASE UP TO 2,992,500 AMERICAN DEPOSITARY SHARES AND 3,750,000 SERIES A WARRANTS TO PURCHASE UP TO 3,750,000 AMERICAN DEPOSITARY SHARES AND PLACEMENT AGENT WARRANTS TO PURCHASE UP TO 187,500 AM |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of princip |
|
| February 1, 2024 |
Evaxion Biotech Announces Pricing of $15 Million Public Offering Exhibit 99.1 Evaxion Biotech Announces Pricing of $15 Million Public Offering COPENHAGEN, Denmark, Feb. 1, 2024 (GLOBE NEWSWIRE) - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares |
|
| January 31, 2024 |
430 Park Avenue | New York, New York 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC Exhibit 1.1 Execution Version September 27, 2023 STRICTLY CONFIDENTIAL Evaxion Biotech A/S Dr. Neergaards Vej SF 2970 Hørsholm Denmark Attn: Christian Kanstrup, Chief Executive Officer This letter agreement (this “Agreement”) constitutes the agreement between Evaxion Biotech A/S (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive underwriter, |
|
| January 31, 2024 |
As filed with the Securities and Exchange Commission on January 31, 2024 As filed with the Securities and Exchange Commission on January 31, 2024 Registration Statement No. |
|
| January 31, 2024 |
As filed with the Securities and Exchange Commission on January 31, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 31, 2024 Registration Statement No. |
|
| January 31, 2024 |
430 Park Avenue | New York, New York 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC Exhibit 1.1 Execution Version September 27, 2023 STRICTLY CONFIDENTIAL Evaxion Biotech A/S Dr. Neergaards Vej SF 2970 Hørsholm Denmark Attn: Christian Kanstrup, Chief Executive Officer This letter agreement (this “Agreement”) constitutes the agreement between Evaxion Biotech A/S (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive underwriter, |
|
| January 30, 2024 |
Exhibit 4.4 PREFUNDED WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES EVAXION BIOTECH A/S Warrant ADSs: Initial Exercise Date: , 2024 THIS PREFUNDED WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limi |
|
| January 30, 2024 |
Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Hørsholm Telephone: +45 31 31 97 53 Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Hørsholm Denmark Telephone: +45 31 31 97 53 January 30, 2024 U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. Alan Campbell Re: Evaxion Biotech A/S Registration Statement on Form F-1 (File No. 333-276505) Acceleration Request Requested Dat |
|
| January 30, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM F-1 (Form Type) Evaxion Biotech A/S (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares DKK 1 nominal value (1)(2)(3) 457(o) — — $ 15,000,000. |
|
| January 30, 2024 |
SERIES A WARRANT TO SUBSCRIBE FOR ORDINARY SHARES EXHIBIT 4.5 SERIES A WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES EVAXION BIOTECH A/S Warrant ADSs: Initial Exercise Date: , 2024 THIS SERIES A WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject |
|
| January 30, 2024 |
As filed with the Securities and Exchange Commission on January 30, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 30, 2024 Registration Statement No. |
|
| January 30, 2024 |
Exhibit 4.6 PLACEMENT AGENT WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES EVAXION BIOTECH A/S Warrant ADSs: Initial Exercise Date: , 2024 THIS PLACEMENT AGENT WARRANT TO SUBSCRIBE FOR ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject |
|
| January 30, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of , 2024, is between Evaxion Biotech A/S, a public limited liability company incorporated under the laws of the Kingdom of Denmark (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Pur |
|
| January 26, 2024 |
VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 Exhibit 1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion Biotech A/S. Selskabet driver tillige virksomhed under binavnet NovVac A/S. 1.1 The name of the Company is Evaxion Biotech A/S. The Company also carries on business under the secondary name NovVac A/S. 1.2 Selskabets formål er at skabe |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principa |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principa |
|
| January 24, 2024 |
Exhibit 99.1 Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets January 24, 2024 · Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine solutions becomes feasible and highly promising for patients in need · Transformative Vaccine Concept: Thi |
